Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

154.67USD
20 Jan 2017
Change (% chg)

$0.87 (+0.57%)
Prev Close
$153.80
Open
$154.71
Day's High
$155.35
Day's Low
$153.82
Volume
3,067,372
Avg. Vol
3,749,335
52-wk High
$176.85
52-wk Low
$133.64

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 1.15
Market Cap(Mil.): $114,415.30
Shares Outstanding(Mil.): 743.92
Dividend: 1.15
Yield (%): 2.99

Financials

  AMGN.O Industry Sector
P/E (TTM): 15.36 44.51 30.50
EPS (TTM): 10.01 -- --
ROI: 11.47 -1.38 14.85
ROE: 25.83 -1.00 16.27

Trump's health pick set to defend investments at U.S. Senate hearing

WASHINGTON, Jan 18 President-elect Donald Trump's nominee for health secretary was expected to face hard questions from a U.S. Senate panel on Wednesday about his personal stock investments and proposals to dismantle Obamacare.

Jan 18 2017

Regeneron CEO says Amgen not putting patients first in patent dispute

Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

Jan 09 2017

UPDATE 1-Regeneron CEO says Amgen not putting patients first in patent dispute

Jan 9 Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

Jan 09 2017

Regeneron CEO says Amgen not putting patients first in patent dispute

Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

Jan 09 2017

CORRECTED-Regeneron CEO says Amgen not putting patients first in patent dispute

Jan 9 Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.

Jan 09 2017

BRIEF-Amgen comments on Delaware court's ruling on PCSK9 patent litigation

* Amgen statement on January 9, 2017, U.S. District court decision

Jan 09 2017

BRIEF-Davita enters into new sourcing and supply agreement with Amgen

* Davita enters into new sourcing and supply agreement with Amgen and initiates 2017 kidney care guidance

Jan 09 2017

BRIEF-Amgen and Davita enter into new sourcing and supply agreement

* Amgen and Davita enter into new sourcing and supply agreement

Jan 09 2017

BRIEF-Amgen, Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

* Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Jan 09 2017

BRIEF-Court grants permanent injunction for infringement of Amgen's Repatha patents

* Court grants permanent injunction for infringement of Amgen's repatha patents

Jan 05 2017

Earnings vs. Estimates